Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to -$34.4 million.

  • Century Therapeutics' Net Income towards Common Stockholders fell 1023.51% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.5 million, marking a year-over-year increase of 7961.75%. This contributed to the annual value of -$126.6 million for FY2024, which is 739.71% up from last year.
  • Per Century Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$34.4 million for Q3 2025, which was down 1023.51% from -$32.5 million recorded in Q2 2025.
  • Century Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $76.6 million during Q1 2025, with a 5-year trough of -$39.4 million in Q4 2023.
  • Its 4-year average for Net Income towards Common Stockholders is -$25.6 million, with a median of -$31.7 million in 2022.
  • In the last 5 years, Century Therapeutics' Net Income towards Common Stockholders crashed by 2436.4% in 2023 and then skyrocketed by 37282.45% in 2025.
  • Over the past 4 years, Century Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$31.7 million in 2022, then fell by 24.36% to -$39.4 million in 2023, then grew by 8.45% to -$36.1 million in 2024, then grew by 4.58% to -$34.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$34.4 million for Q3 2025, versus -$32.5 million for Q2 2025 and $76.6 million for Q1 2025.